Abstract
The variability in myelosuppression after chemotherapy for acute myeloid leukaemia (AML) can affect its prognosis; however, the underlying mechanism remains controversial. In the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study, we showed that prolonged neutropenia was associated with high overall survival (P = 0·011) and low frequency of relapse (P = 0·042) in patients without granulocyte-colony stimulating factor (G-CSF) who completed the indicated treatment protocol. Our data indicate that predisposition to prolonged neutropenia after chemotherapy is correlated with a better outcome of AML treatment. Our results promote the usage of individualised drug dosing strategies to improve the therapeutic outcome in AML patients.
Original language | English |
---|---|
Pages (from-to) | 176-180 |
Number of pages | 5 |
Journal | British Journal of Haematology |
Volume | 193 |
Issue number | 1 |
DOIs | |
Publication status | Published - Apr 2021 |
Keywords
- acute myeloid leukaemia
- chemosensitivity
- children
- myelosuppression
- neutropenia
ASJC Scopus subject areas
- Hematology